Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be more effective than chemotherapy in the treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, in addition to EGFR-sensitive mutations, the genetic factors that affect the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hualin, Liu, Meilian, Dai, Zhiwei, Li, Shujun, Luo, Yiping, Wang, Yongcun, Su, Wenmei, Cai, Weijing, Yang, Donghong, Huang, Jian, Yang, Zhixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481595/
https://www.ncbi.nlm.nih.gov/pubmed/32953500
http://dx.doi.org/10.21037/tlcr-20-679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481595/
https://www.ncbi.nlm.nih.gov/pubmed/32953500
http://dx.doi.org/10.21037/tlcr-20-679

Ejemplares similares